Skip to content
OpenCapital
Get started

Pfizer PFE Total accrued rebates and other sales-related accruals

Other financials

Income statement

See full
Revenue$14.5B+5.4%
Gross profit$10.9B+0.3%
Net income$2.7B-9.4%
EPS (diluted)$0.47-9.6%

Balance sheet

See full
Cash & equivalents$1.8B+18.8%
Total debt$64.4B+5.0%
Total equity$90.1B-0.3%
Total assets$207.62B-0.2%

Cash flow

See full
Operating cash flow$2.6B+12.0%
CapEx$436.0M-22.7%
Free cash flow$2.2B+23.0%

Valuation

See full
Market cap$143.68B+11.1%
Enterprise value$206.35B+9.2%
P/E11.9×—
P/S2.3×+0.2×

Profitability

See full
Gross margin73.5%+1.2pp
Net margin15.7%—

Returns & leverage

See full
Return on equity10.6%—
Debt / equity0.7×0.0×
Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept pfe:RebatesAndOtherSalesRelatedAccruals.

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's total accrued rebates and other sales-related accruals.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pfizer's total accrued rebates and other sales-related accruals?
Pfizer (PFE) reported total accrued rebates and other sales-related accruals of $11.55B in Q1 2026.
How has Pfizer's total accrued rebates and other sales-related accruals changed year-over-year?
Pfizer's total accrued rebates and other sales-related accruals increased by 5.5% year-over-year, from $10.95B to $11.55B.
What is the long-term trend for Pfizer's total accrued rebates and other sales-related accruals?
Over 3 years (2022 to 2025), Pfizer's total accrued rebates and other sales-related accruals has grown at a 20.2% compound annual growth rate (CAGR), from $6.72B to $11.67B.